These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33360197)

  • 1. MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice.
    Wang L; Lei W; Zhang S; Yao L
    Bioorg Med Chem; 2021 Jan; 30():115954. PubMed ID: 33360197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of combination of anakinra and MCC950 against acute lung injury is achieved through suppression of the NF-κB-mediated-MAPK and NLRP3-caspase pathways.
    Wang X; Chen S; Zhao L; Shi X
    Int Immunopharmacol; 2021 Aug; 97():107506. PubMed ID: 34022766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
    Li Y; Li H; Liu S; Pan P; Su X; Tan H; Wu D; Zhang L; Song C; Dai M; Li Q; Mao Z; Long Y; Hu Y; Hu C
    Mol Immunol; 2018 Jul; 99():134-144. PubMed ID: 29783158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
    PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
    Zhang W; Ba G; Tang R; Li M; Lin H
    Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages.
    Zeng W; Wu D; Sun Y; Suo Y; Yu Q; Zeng M; Gao Q; Yu B; Jiang X; Wang Y
    Sci Rep; 2021 Sep; 11(1):19305. PubMed ID: 34588488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Geranylgeranyl diphosphate synthase 1 knockdown suppresses NLRP3 inflammasome activity via promoting autophagy in sepsis-induced acute lung injury.
    Li D; Li C; Wang T; Zhang C; Zhu Z; Zhang G; Fang B
    Int Immunopharmacol; 2021 Nov; 100():108106. PubMed ID: 34530204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
    Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
    Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis.
    Zhang L; Jiang YH; Fan C; Zhang Q; Jiang YH; Li Y; Xue YT
    Biomed Pharmacother; 2021 Nov; 143():112133. PubMed ID: 34474337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
    Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
    Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
    Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
    Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCC950 attenuated early brain injury by suppressing NLRP3 inflammasome after experimental SAH in rats.
    Luo Y; Lu J; Ruan W; Guo X; Chen S
    Brain Res Bull; 2019 Mar; 146():320-326. PubMed ID: 30716395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice.
    Dong L; Zhu YH; Liu DX; Li J; Zhao PC; Zhong YP; Chen YQ; Xu W; Zhu ZQ
    J Immunol Res; 2019; 2019():7264383. PubMed ID: 30937316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation.
    Jiang M; Li R; Lyu J; Li X; Wang W; Wang Z; Sheng H; Zhang W; Karhausen J; Yang W
    J Neuroinflammation; 2020 Aug; 17(1):256. PubMed ID: 32867797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
    Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
    Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MCC950, the NLRP3 Inhibitor, Protects against Cartilage Degradation in a Mouse Model of Osteoarthritis.
    Ni B; Pei W; Qu Y; Zhang R; Chu X; Wang Y; Huang X; You H
    Oxid Med Cell Longev; 2021; 2021():4139048. PubMed ID: 34777685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NLRP3 inflammasome contributes to inflammation-induced morphological and metabolic alterations in skeletal muscle.
    Eggelbusch M; Shi A; Broeksma BC; Vázquez-Cruz M; Soares MN; de Wit GMJ; Everts B; Jaspers RT; Wüst RCI
    J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):3048-3061. PubMed ID: 35978267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FSTL1 aggravates OVA-induced inflammatory responses by activating the NLRP3/IL-1β signaling pathway in mice and macrophages.
    Wang Y; Zhang D; Liu T; Wang JF; Wu JX; Zhao JP; Xu JW; Zhang JT; Dong L
    Inflamm Res; 2021 Jul; 70(7):777-787. PubMed ID: 34076707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.